


# 22

PATENT 1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of  
Guo et al.

Examiner: Unknown

Art Unit: 1646

Application No.: 09/933,780

Filed: August 21, 2001

Title: **MEMBRANE PENETRATING PEPTIDES  
AND USES**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Date of Deposit

Signature

*July 16, 2003*  
*Diana Cooper*

RECEIVED  
JUL 22 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3800  
Telefax (908) 231-2626  
Aventis Docket No. HMR2053USNP1

☒

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet 1 of 2

**Complete if Known**

Application Number	09/933,780
Filing Date	08-21-2001
First Named Inventor	GUO
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket Number	USHMR2053 - US - NP - 1

A circular black ink stamp from the Intellectual Property Office (IPO). The text "IPO" is at the top, "JUL 18 2003" is in the center, and "PATENT &amp; TRADE MARKS" is at the bottom. The stamp is partially overlapping the right edge of the document.

RECEIVED  
JUL 22 2003  
TECH CENTER 1600/2900  
IP - 1  
mms, Lines,  
relevant  
s Relevant

[illegible][illegible]

Examiner  
Signature

Date	
Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/933,780
Filing Date	08-21-2001
First Named Inventor	GUO
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket Number	USHMR2053 - US - NP - 1

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		D.J. Mitchell et al., Polyarginine Enters Cells More Efficiently Than Other Polycationic Homopolymers, Journal of Peptide Research, Vol. 56, No. 5, Nov. 2000, pages 318-325	
		E. Vives et al., A Truncated HIV-1 TAT Protein Basic Domain Rapidly Translocates Through The Plasma Membrane And Accumulates In the Cell Nucleus, Journ. of Biological Chemistry, Vol. 272, No. 25, June 20 1997, pages 16010-16017	
		M. Lindgren et al., Cell-Penetrating Peptides, Trends in Pharmacological Sciences, Elsevier Trends Journal, Vol. 21, No. 3, March 2000, pages 99-103	
		S. Futaki et al., Arginine-rich Peptides, Journal of Biological Chemistry, Vol. 276, No. 8, Nov. 17, 2000, pages 5836-5840	
		S. Schwarze et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, Vol. 285, Sept. 3, 1999, pages 1569-1572	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

### Complete if Known

Application Number	09/933,780
Filing Date	08-21-2001
First Named Inventor	GUO
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket Number	USHMR2053 - US - NP - 1

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		D.J. Mitchell et al., Polyarginine Enters Cells More Efficiently Than Other Polycationic Homopolymers, Journal of Peptide Research, Vol. 56, No. 5, Nov. 2000, pages 318-325	
		E. Vives et al., A Truncated HIV-1 TAT Protein Basic Domain Rapidly Translocates Through The Plasma Membrane And Accumulates In the Cell Nucleus, Journ. of Biological Chemistry, Vol. 272, No. 25, June 20 1997, pages 16010-16017	
		M. Lindgren et al., Cell-Penetrating Peptides, Trends in Pharmacological Sciences, Elsevier Trends Journal, Vol. 21, No. 3, March 2000, pages 99-103	
		S. Futaki et al., Arginine-rich Peptides, Journal of Biological Chemistry, Vol. 276, No. 8, Nov. 17, 2000, pages 5836-5840	
		S. Schwarze et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, Vol. 285, Sept. 3, 1999, pages 1569-1572	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.